Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator with some beta-adrenergic agonist activity. It is believed to increase blood flow by relaxing vascular smooth muscle.
## Primary Indications
* Peripheral vascular disease (e.g., intermittent claudication, vasospasm)
* Cerebrovascular insufficiency
Note: The efficacy of isoxsuprine for these indications is not definitively established by rigorous clinical trials.
## Adult Dosing
* **Intermittent Claudication/Peripheral Vascular Disease:** 10-20 mg orally 3 to 4 times daily.
* **Cerebrovascular Insufficiency:** 10-20 mg orally 3 to 4 times daily.
* Maximum dose is generally considered to be 80 mg per day.
## Pediatric Dosing
No established pediatric dosing is available.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment, but caution may be warranted in severe disease.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Use in patients with congenital heart defects or arrhythmias.
## Adverse Effects
* **Cardiovascular:** Hypotension, tachycardia, dizziness, flushing.
* **Gastrointestinal:** Nausea, vomiting, stomach upset, abdominal distress.
* **Other:** Weakness, nervousness, drowsiness, rash.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine's vasodilatory effects may potentiate the hypotensive effects of antihypertensive medications.
* **Epinephrine:** May antagonize the vasodilating effects of isoxsuprine.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of peripheral vascular disease or cerebrovascular insufficiency.
* Signs of adverse effects.
## Clinical Pearls
* Onset of action is typically within 30 minutes, with peak effects at 1 to 2 hours, and duration of action of approximately 4 hours.
* Efficacy is variable and response can be patient-specific.
***
*Disclaimer: This information is intended for clinical professionals. Always consult the most current prescribing information and relevant guidelines for definitive drug management decisions.*
